JMP Securities Maintains Market Outperform on BioCryst Pharma, Raises Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben maintains a Market Outperform rating on BioCryst Pharma (NASDAQ:BCRX) and raises the price target from $15 to $16.
August 06, 2024 | 5:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst Jonathan Wolleben maintains a Market Outperform rating on BioCryst Pharma and raises the price target from $15 to $16.
The raised price target and maintained Market Outperform rating from JMP Securities are positive signals for BioCryst Pharma, likely leading to increased investor confidence and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100